Regulatory News: Medincell (Paris:MEDCL): Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell's portfolio and R&D pipeline at the Jefferies Global Healthcare Conference on
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Phase 3 SOLARIS Trial Demonstrates Potential of TEV-'749 in Schizophrenia psychiatrictimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from psychiatrictimes.com Daily Mail and Mail on Sunday newspapers.
MONTPELLIER, France, April 08, 2024 Regulatory News: Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM. If proven safe, effective, and acceptable, mdc-STM could have a significant impact on transmission of malaria among vulnerable populations in high-transmission areas.
MedinCell to Present at the 23rd Annual Needham Virtual Healthcare Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.